A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting

NCT07109375 ·Status: NOT_YET_RECRUITING

Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion

NCT05186324 ·Status: COMPLETED

Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

NCT06941025 ·Status: RECRUITING

A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

NCT06904261 ·Status: RECRUITING ·Phase: PHASE3

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

NCT03614234 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

NCT03425539 ·Status: COMPLETED ·Phase: PHASE3

German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa

NCT06095713 ·Status: ACTIVE_NOT_RECRUITING

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

NCT03500094 ·Status: COMPLETED ·Phase: PHASE3

A Study of Patients With Fabry Disease (US Specific)

NCT06906367 ·Status: RECRUITING

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00283959 ·Status: COMPLETED ·Phase: PHASE2

Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks

NCT03180840 ·Status: COMPLETED ·Phase: PHASE3

French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat

NCT04602364 ·Status: COMPLETED

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

NCT01298141 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease

NCT05710692 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Extension Study of PRX-102 for up to 60 Months

NCT01981720 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease

NCT06819514 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

A Study of Fabrazyme in Pediatric Patients With Fabry Disease

NCT00074958 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

NCT03737214 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study

NCT03683966 ·Status: UNKNOWN

Home Therapy With Replagal in Fabry Disease

NCT01355146 ·Status: COMPLETED

A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00283933 ·Status: COMPLETED ·Phase: PHASE2

Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease

NCT06114329 ·Status: RECRUITING ·Phase: PHASE2

Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease

NCT00487630 ·Status: UNKNOWN ·Phase: PHASE4

Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

NCT03018730 ·Status: COMPLETED ·Phase: PHASE3

Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)

NCT01433354 ·Status: TERMINATED ·Phase: PHASE2/PHASE3